Advertisement

High-Throughput Metabolomics Based on Direct Mass Spectrometry Analysis in Biomedical Research

Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 1978)

Abstract

Metabolomics based on direct mass spectrometry analysis shows a great potential in biomedical research because of its high-throughput screening capability and wide metabolome coverage. This chapter contains detailed protocols to perform comprehensive metabolomic fingerprinting of multiple biological samples (serum, plasma, urine, brain, liver, spleen, thymus) by using complementary analytical platforms. The most important issues to be considered are discussed, including sample treatment, metabolomic analysis, raw data preprocessing, and data analysis.

Keywords

Metabolomics Direct mass spectrometry analysis Direct infusion Flow injection High-throughput 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Emwas AHM, Salek RM, Griffin JL, Merzaban J (2013) NMR based metabolomics in human disease diagnosis: applications, limitations, and recommendations. Metabolomics 9:1048–1072Google Scholar
  2. 2.
    Theodoridis G, Gika HG, Wilson ID (2011) Mass spectrometry-based holistic analytical approaches for metabolite profiling in systems biology studies. Mass Spectrom Rev 30:884–906PubMedGoogle Scholar
  3. 3.
    González-Domínguez R, Sayago A, Fernández-Recamales A (2017) Metabolomics in Alzheimer’s disease: the need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology. J Chromatogr B Analyt Technol Biomed Life Sci 1071:75–92PubMedGoogle Scholar
  4. 4.
    Gonzalez-Dominguez A, Duran-Guerrero E, Fernandez-Recamales A, Lechuga-Sancho AM, Sayago A, Schwarz M, Segundo C, Gonzalez-Dominguez R (2017) An overview on the importance of combining complementary analytical platforms in metabolomic research. Curr Top Med Chem 17:3289–3295PubMedGoogle Scholar
  5. 5.
    Draper J, Lloyd AJ, Goodacre R, Beckmann M (2013) Flow infusion electrospray ionisation mass spectrometry for high throughput, non-targeted metabolite fingerprinting: a review. Metabolomics 9:S4–S29Google Scholar
  6. 6.
    González-Domínguez R, Sayago A, Fernández-Recamales A (2017) Direct infusion mass spectrometry for metabolomic phenotyping of diseases. Bioanalysis 9:131–148PubMedGoogle Scholar
  7. 7.
    Guo Y, Wang X, Qiu L, Qin X, Liu H, Wang Y, Li F, Wang X, Chen G, Song G, Li F, Guo S, Li Z (2012) Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry. Clin Chim Acta 414:135–141PubMedGoogle Scholar
  8. 8.
    Cameron SJ, Lewis KE, Beckmann M, Allison GG, Ghosal R, Lewis PD, Mur LA (2016) The metabolomic detection of lung cancer biomarkers in sputum. Lung Cancer 94:88–95PubMedGoogle Scholar
  9. 9.
    Lokhov PG, Kharybin ON, Archakov AI (2012) Diagnosis of lung cancer based on direct-infusion electrospray mass spectrometry of blood plasma metabolites. Int J Mass Spectrom 309:200–205Google Scholar
  10. 10.
    Lokhov PG, Dashtiev MI, Moshkovskii SA, Archakov AI (2010) Metabolite profiling of blood plasma of patients with prostate cancer. Metabolomics 6:156–163Google Scholar
  11. 11.
    Lin L, Yu Q, Yan X, Hang W, Zheng J, Xing J, Huang B (2010) Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer. Analyst 135:2970–2978PubMedGoogle Scholar
  12. 12.
    Ritchie SA, Akita H, Takemasa I, Eguchi H, Pastural E, Nagano H, Monden M, Doki Y, Mori M, Jin W, Sajobi TT, Jayasinghe D, Chitou B, Yamazaki Y, White T, Goodenowe DB (2013) Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer 13:416PubMedPubMedCentralGoogle Scholar
  13. 13.
    Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB (2010) Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 8:13PubMedPubMedCentralGoogle Scholar
  14. 14.
    Li F, Qin X, Chen H, Qiu L, Guo Y, Liu H, Chen G, Song G, Wang X, Li F, Guo S, Wang B, Li Z (2013) Lipid profiling for early diagnosis and progression of colorectal cancer using direct-infusion electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun Mass Spectrom 27:24–34PubMedGoogle Scholar
  15. 15.
    Williams MD, Zhang X, Park JJ, Siems WF, Gang DR, Resar LM, Reeves R, Hill HH Jr (2015) Characterizing metabolic changes in human colorectal cancer. Anal Bioanal Chem 407:4581–4595PubMedGoogle Scholar
  16. 16.
    Lokhov PG, Trifonova OP, Maslov DL, Balashova EE, Archakov AI, Shestakova EA, Shestakova MV, Dedov II (2014) Diagnosing impaired glucose tolerance using direct infusion mass spectrometry of blood plasma. PLoS One 9:e105343PubMedPubMedCentralGoogle Scholar
  17. 17.
    Renner S, Römisch-Margl W, Prehn C, Krebs S, Adamski J, Göke B, Blum H, Suhre K, Roscher AA, Wolf E (2012) Changing metabolic signatures of amino acids and lipids during the prediabetic period in a pig model with impaired incretin function and reduced β-cell mass. Diabetes 61:2166–2175PubMedPubMedCentralGoogle Scholar
  18. 18.
    González-Domínguez R, Mateos RM, Lechuga-Sancho AM, González-Cortés JJ, Corrales-Cuevas M, Rojas-Cots JA, Segundo C, Schwarz M (2017) Synergic effects of sugar and caffeine on insulin-mediated metabolomic alterations after an acute consumption of soft drinks. Electrophoresis 38:2313–2322PubMedGoogle Scholar
  19. 19.
    Antunes LC, Han J, Pan J, Moreira CJ, Azambuja P, Borchers CH, Carels N (2013) Metabolic signatures of triatomine vectors of Trypanosoma cruzi unveiled by metabolomics. PLoS One 8:e77283PubMedPubMedCentralGoogle Scholar
  20. 20.
    Ferreira MS, de Oliveira DN, de Oliveira RN, Allegretti SM, Catharino RR (2014) Screening the life cycle of Schistosoma mansoni using high-resolution mass spectrometry. Anal Chim Acta 845:62–69PubMedGoogle Scholar
  21. 21.
    de Francisco TMG, Zaramella IF, Gasparetto JC, Cerqueira LB, Piantavini MS, Pontarolo R, Campos FR (2009) Rapid detection of aspergillosis in immunocompromised patients using DIMS and chemometric analysis. Anal Methods 7:6346–6351Google Scholar
  22. 22.
    Jansson J, Willing B, Lucio M, Fekete A, Dicksved J, Halfvarson J, Tysk C, Schmitt-Kopplin P (2009) Metabolomics reveals metabolic biomarkers of Crohn’s disease. PLoS One 4:e6386PubMedPubMedCentralGoogle Scholar
  23. 23.
    Lorenzo-Tejedor M, de la Cámara C, Lopez-Anton R, Bailon R, Aguiló J, Bernal-Ruiz ML (2015) Direct infusion electrospray mass spectrometry as a new non-invasive tool for serum metabolomics in induced-stress subjects. Eur J Psychiat 29:259–275Google Scholar
  24. 24.
    Anand S, Young S, Esplin MS, Peaden B, Tolley HD, Porter TF, Varner MW, D’Alton ME, Jackson BJ, Graves SW (2016) Detection and confirmation of serum lipid biomarkers for preeclampsia using direct infusion mass spectrometry. J Lipid Res 57:687–696PubMedPubMedCentralGoogle Scholar
  25. 25.
    González-Domínguez R, García-Barrera T, Gómez-Ariza JL (2014) Using direct infusion mass spectrometry for serum metabolomics in Alzheimer’s disease. Anal Bioanal Chem 406:7137–7148PubMedGoogle Scholar
  26. 26.
    González-Domínguez R, García-Barrera T, Gómez-Ariza JL (2012) Metabolomic approach to Alzheimer’s disease diagnosis based on mass spectrometry. Chem Papers 66:829–835Google Scholar
  27. 27.
    González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL (2015) Application of metabolomics based on direct mass spectrometry analysis for the elucidation of altered metabolic pathways in serum from the APP/PS1 transgenic model of Alzheimer’s disease. J Pharm Biomed Anal 107:378–385PubMedGoogle Scholar
  28. 28.
    González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL (2015) Metabolomic research on the role of interleukin-4 in Alzheimer’s disease. Metabolomics 11:1175–1183Google Scholar
  29. 29.
    González-Domínguez R, García-Barrera T, Gómez-Ariza JL (2014) Metabolomic study of lipids in serum for biomarker discovery in Alzheimer’s disease using direct infusion mass spectrometry. J Pharm Biomed Anal 98:321–326PubMedGoogle Scholar
  30. 30.
    González-Domínguez R, García-Barrera T, Gómez-Ariza JL (2014) Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer’s disease. J Proteome 104:37–47Google Scholar
  31. 31.
    González-Domínguez R, Castilla-Quintero R, García-Barrera T, Gómez-Ariza JL (2014) Development of a metabolomic approach based on urine samples and direct infusion mass spectrometry. Anal Biochem 465:20–27PubMedGoogle Scholar
  32. 32.
    González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL (2015) Metabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer’s disease by direct infusion mass spectrometry. J Pharm Biomed Anal 102:425–435PubMedGoogle Scholar
  33. 33.
    González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL (2015) High throughput multi-organ metabolomics in the APP/PS1 mouse model of Alzheimer’s disease. Electrophoresis 36:2237–2249PubMedGoogle Scholar
  34. 34.
    González-Domínguez R, Rupérez FJ, García-Barrera T, Barbas C, Gómez-Ariza JL (2016) Metabolomic-driven elucidation of pathological mechanisms associated with Alzheimer’s disease and mild cognitive impairment. Curr Alzheimer Res 13:641–653PubMedGoogle Scholar
  35. 35.
    González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL (2015) Deciphering metabolic abnormalities associated with Alzheimer’s disease in the APP/PS1 mouse model using integrated metabolomic approaches. Biochimie 110:119–128PubMedGoogle Scholar
  36. 36.
    González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL (2014) Region-specific metabolic alterations in the brain of the APP/PS1 transgenic mice of Alzheimer’s disease. Biochim Biophys Acta 1842:2395–2402PubMedGoogle Scholar
  37. 37.
    González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL (2015) Metabolomics reveals significant impairments in the immune system of the APP/PS1 transgenic mice of Alzheimer’s disease. Electrophoresis 36:577–587PubMedGoogle Scholar
  38. 38.
    González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL (2015) Metabolomic investigation of systemic manifestations associated with Alzheimer’s disease in the APP/PS1 transgenic mouse model. Mol BioSyst 11:2429–2440PubMedGoogle Scholar
  39. 39.
    González-Domínguez R, García-Barrera T, Gómez-Ariza JL (2015) Metabolite profiling for the identification of altered metabolic pathways in Alzheimer’s disease. J Pharm Biomed Anal 107:75–81PubMedGoogle Scholar
  40. 40.
    González-Domínguez R, García A, García-Barrera T, Barbas C, Gómez-Ariza JL (2014) Metabolomic profiling of serum in the progression of Alzheimer’s disease by capillary electrophoresis-mass spectrometry. Electrophoresis 35:3321–3330PubMedGoogle Scholar
  41. 41.
    Lin S, Liu H, Kanawati B, Liu L, Dong J, Li M, Huang J, Schmitt-Kopplin P, Cai Z (2013) Hippocampal metabolomics using ultrahigh-resolution mass spectrometry reveals neuroinflammation from Alzheimer’s disease in CRND8 mice. Anal Bioanal Chem 405:5105–5117PubMedGoogle Scholar
  42. 42.
    Lin S, Kanawati B, Liu L, Witting M, Li M, Huang J, Schmitt-Kopplin P, Cai Z (2014) Ultrahigh resolution mass spectrometry-based metabolic characterization reveals cerebellum as a disturbed region in two animal models. Talanta 118:45–53PubMedGoogle Scholar
  43. 43.
    González-Domínguez R, García-Barrera T, Gómez-Ariza JL (2015) Application of a novel metabolomic approach based on atmospheric pressure photoionization mass spectrometry using flow injection analysis for the study of Alzheimer’s disease. Talanta 131:480–489PubMedGoogle Scholar
  44. 44.
    Sangster T, Major H, Plumb R, Wilson AJ, Wilson ID (2006) A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. Analyst 131:1075–1078PubMedGoogle Scholar
  45. 45.
    van den Berg RA, Hoefsloot HCJ, Westerhuis JA, Smilde AK, van der Werf MJ (2006) Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 7:142PubMedPubMedCentralGoogle Scholar
  46. 46.
    Hernandes VV, Barbas C, Dudzik D (2017) A review of blood sample handling and pre-processing for metabolomics studies. Electrophoresis 38:2232–2241PubMedGoogle Scholar
  47. 47.
    Yuille M, Illig T, Hveem K, Schmitz G, Hansen J, Neumaier M, Tybring G, Wichmann E, Ollier B (2010) Laboratory management of samples in biobanks: European consensus expert group report. Biopreserv Biobank 8:65–69PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Chemistry, Faculty of Experimental SciencesUniversity of HuelvaHuelvaSpain
  2. 2.International Campus of Excellence CeiA3University of HuelvaHuelvaSpain
  3. 3.Department of PediatricsHospital Universitario Puerta del MarCádizSpain
  4. 4.Institute of Research and Innovation in Biomedical Sciences of the Province of Cádiz (INiBICA)CádizSpain
  5. 5.“Salus Infirmorum” Faculty of NursingUniversity of CádizCádizSpain
  6. 6.Instituto de Investigación Vitivinícola y Agroalimentario (IVAGRO)University of CádizPuerto RealSpain
  7. 7.Department of Analytical ChemistryUniversity of CádizPuerto RealSpain
  8. 8.Department of Mother and Child Health and Radiology, Faculty of MedicineUniversity of CádizCádizSpain

Personalised recommendations

Cite protocol

Buy options